Managed Care & Health Insurance

Margin recovery is real but purchased through deliberate membership contraction.

Across UNH, ELV, HUM, CNC, MOH, CVS, and AGL, the operative strategy this cycle is identical: exit unprofitable geographies, products, and populations to restore underwriting discipline, accepting near-term membership losses in exchange for MCR improvement. UNH shed 1.825 million total medical members while delivering a 52% improvement in earnings from operations; AGL accepted a 10% MA membership decline and converted a 1,550 basis point MSER improvement into its first sustained quarterly profit. This is not a cyclical correction; it is a structural repricing of risk that permanently resets the membership-margin tradeoff across the sector.

Medicare Advantage rate inadequacy is confirmed structural, not transitory.

UNH explicitly stated that the 2027 MA Final Notice 'remains below' forward medical cost trend, compounding multi-year base rate shortfalls that have forced benefit redesign and county exits. ELV's 2027 Star Ratings show 4-star-eligible membership falling from 55% to 49%, directly compressing 2028 bonus payments; CVS disclosed a parallel decline from more than 81% to more than 69%. CMS risk adjustment model revisions are simultaneously reducing per-member funding for high-acuity populations, creating a dual-channel funding squeeze that no single repricing cycle can resolve.

PBM business models are being legislatively restructured in real time.

The Consolidated Appropriations Act of 2026 mandates full rebate pass-through to commercial plan sponsors and delinks Part D PBM compensation from drug prices effective 2028, with ELV explicitly acknowledging potential adverse effects on CarelonRx and CI guiding pharmacy benefit services income down single digits in 2027 for the first time. CI's Signature fee-based model has moved from design to active manufacturer recontracting, and the DOL's newly finalized PBM fee disclosure rule adds a compliance layer that overlaps with and in some areas contradicts the CAA of 2026. The direction of travel is irreversible: rebate-based PBM economics are being legislated out of existence on a defined timeline.

CVS separation and Cigna portfolio pruning redraw sector competitive boundaries.

CVS Health announced a planned tax-free separation into two independent public companies targeting H1 2028, splitting Aetna, Caremark, Specialty, Oak Street, and Signify from the retail pharmacy and community health business. CI has already divested its Medicare Advantage businesses to HCSC and is exiting the ACA individual exchange market entirely as of January 1, 2027, concentrating capital on commercial employer and stop loss lines where premium rate increases are delivering margin expansion. These moves leave the integrated insurer-PBM-care delivery model as a contested rather than settled competitive form, with no other tracked company replicating CVS's full pre-separation stack.